CEO, President and Director Oliviero James F III sold 10,261 shares of Checkpoint Therapeutics Inc. [CKPT]


Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Checkpoint Therapeutics Inc. shares valued at $48,945 were sold by Oliviero James F III on Feb 01. At $4.77 per share, Oliviero James F III sold 10,261 shares. The insider’s holdings dropped to 182,121 shares worth approximately $0.92 million following the completion of this transaction.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Also, GRAY WILLIAM GARRETT sold 3,154 shares, netting a total of over 15,108 in proceeds. Following the sale of shares at $4.79 each, the insider now holds 49,379 shares.

Before that, Oliviero James F III had sold 3,817 shares from its account. In a trade valued at $25,761, the CEO, President and Director traded Checkpoint Therapeutics Inc. shares for $6.75 each. Upon closing the transaction, the insider’s holdings decreased to 3,817 shares, worth approximately $0.97 million.

Analysts at B. Riley Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in early June. As of January 20, 2021, Cantor Fitzgerald has initiated its “an Overweight” rating for CKPT. Earlier on May 29, 2019, Lake Street initiated its rating. Their recommendation was “a Buy” for CKPT stock.

Analyzing CKPT Stock Performance

On Thursday, Checkpoint Therapeutics Inc. [NASDAQ: CKPT] rose 2.85% to $5.06. The stock’s lowest price that day was $4.80, but it reached a high of $5.50 in the same session. During the last five days, there has been a surge of approximately 19.06%. Over the course of the year, Checkpoint Therapeutics Inc. shares have dropped approximately -0.98%. Shares of the company reached a 52-week high of $8.15 on 01/13/23 and a 52-week low of $4.00 on 02/23/23. A 50-day SMA is recorded $5.28, while a 200-day SMA reached $9.20. Nevertheless, trading volume fell to 0.51 million shares from 78900.0 shares the previous day.

Support And Resistance Levels for Checkpoint Therapeutics Inc. (CKPT)

According to the 24-hour chart, there is a support level at 4.74, which, if violated, would cause prices to drop to 4.42. In the upper region, resistance lies at 5.44. The next price resistance is at 5.82. RSI (Relative Strength Index) is 49.83 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.04, which suggests the price will decrease in the coming days. Percent R is at 46.73%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Checkpoint Therapeutics Inc. subject to short interest?

Stocks of Checkpoint Therapeutics Inc. saw a sharp steep in short interest on Jan 30, 2023 dropping by 55450.0 shares to 0.28 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 0.33 million shares. A decline of -20.07% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.95 of the overall float, the days-to-cover ratio (short ratio) decline to 0.95.

Which companies own the most shares of Checkpoint Therapeutics Inc. (CKPT)?

According to Armistice Capital LLC filings, the company currently owns 691,895 shares, which is about 8.04% of the total CKPT shares outstanding. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $1,493,527. Bank of America, NA acquire a 20,146.00% interest valued at $1.01 million while Jess S. Morgan & Co., Inc. purchased a 75,737 stake. A total of 113,152 shares of Checkpoint Therapeutics Inc. were bought by TwinBeech Capital LP during the quarter, and -448 were sold by BlackRock Fund Advisors. In its current portfolio, Geode Capital Management LLC holds 71,590 shares valued at $0.36 million.

In terms of Checkpoint Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $48.60 in the next 12 months, up nearly 733.33% from the previous closing price of $4.92. Analysts anticipate Checkpoint Therapeutics Inc. stock to reach $96.00 by 2023, with the lowest price target being $15.00. In spite of this, 5 analysts ranked Checkpoint Therapeutics Inc. stock as a Buy at the end of 2023. On December 08, 2017, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $11.


Please enter your comment!
Please enter your name here